| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 55.7MM | +17% |
| Gross Profit | 17.9MM | +15% |
| Cost Of Revenue | - | - |
| Operating Income | -82.5MM | +13% |
| Operating Expenses | 100.4MM | +13% |
| Net Income | -66.9MM | -4% |
| R&D | 47.5MM | +3% |
| G&A | 43.4MM | +7% |
| Interest Expense | 3.6MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Market forces rained on the parade of Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) shareholders today, when...
PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.
At one point Cathie Wood was the hottest money manager on Wall Street. Her family of Ark Invest exchange-traded funds (ETF) grew at a blistering pace, at one point doubling the returns for investors. But the tech sector downturn was hard on her funds, and she has lagged behind the S&P 500. Over the past three years, her ETFs are down an average of 50% while the broad index is up almost 25%. That 75 percentage point delta is a harsh reality for some investors. But it still pays to keep abreast of
Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data. The announcement follows funding from the European Commission and the Estonian government to help Estonia adopt personalized medicine at scale and adapt public health systems to
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan
In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now. NASDAQ Leads The Market On March 12, the Nasdaq Composite Index was […]
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.